Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator
BMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o1010 (Published 21 April 2022) Cite this as: BMJ 2022;377:o1010- Jacqui Wise
- Kent
The Medicines and Healthcare Products Regulatory Agency (MHRA) has strengthened its warning about avoiding pregabalin during pregnancy after new data showed an increased risk of major congenital malformations associated with the drug.1
Pregabalin (brand names Alzain, Axalid, Lecaent, Lyrica, plus generic versions) is commonly used to treat peripheral and central neuropathic pain, generalised anxiety disorder, and epilepsy.
The updated advice follows a Nordic observational study of more than 2700 pregnancies exposed to pregabalin in the first trimester.2
Doctors should provide counselling to patients using pregabalin on the potential risks to an unborn baby and the need to use effective contraception during treatment, the guidance …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.